NCT05517265View on ClinicalTrials.gov

Acalabrutinib in Patients With Chronic Lymphocytic Leukemia With Direct Oral Anticoagulation (CICERO)

Active, not recruitingOBSERVATIONAL

Enrollment

45

Participants

Timeline

Start Date

October 12, 2022

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions

CLL

Interventions

DRUG

Calquence

acalabrutinib (+/- obinutuzumab) according to Calquence® SmPC.

DRUG

Calquence

acalabrutinib according to Calquence® SmPC.

Trial Locations (1)

07318

Prof. Dr. Fenchel & Dr. Winkler MVZ Träger GbR, Saalfeld

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

AstraZeneca

INDUSTRY

lead

iOMEDICO AG

INDUSTRY